(Q39434943)

11 September 2017

Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells (English)

1 reference

11 September 2017

dasatinib monohydrate

1 reference

1 reference

1 reference

1 reference

Lori Rice

1

1 reference

11 September 2017

Sharon Lepler

series ordinal

2

1 reference

11 September 2017

Christina Pampo

series ordinal

3

1 reference

11 September 2017

Dietmar W Siemann

series ordinal

4

1 reference

11 September 2017

language of work or name

1 reference

1 December 2011

1 reference

Clinical & Experimental Metastasis

11 September 2017

1 reference

11 September 2017

29

1 reference

11 September 2017

2

1 reference

11 September 2017

133-142

1 reference

https://scigraph.springernature.com/pub.10.1007/s10585-011-9436-2

11 September 2017

0 references

cites work

Cancer metastasis as a therapeutic target

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

New molecular targets in bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

SRC: a century of science brought to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Regulation of androgen receptor activity by tyrosine phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Docetaxel-based combination therapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Targeting the tumor microenvironment with SRC kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Src continues aging: current and future clinical directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Src kinases as therapeutic targets for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Emerging treatment options for patients with castration-resistant prostate cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22130962

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Regulation of SRC family kinases in human cancers

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22130962

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10585-011-9436-2

1 reference

11 September 2017

1 reference